A well-played inning of 17 long years come to an end when the special provisions of ‘Dividend Distribution Tax’ (DDT) were proposed to be abolished in the Indian Union Budget of 2020 tabled on 1st February 2020. Dividends are considered as an appropriation of after-tax profits and in many jurisdictions, the concept of taxation of dividends is non-existent. DDT in a way served two purposes, the first one being a notion in the minds of investor (corporates and individuals) that they are receiving the dividends tax-free and the second one being efficient tax collection mechanism for the government by making companies responsible for paying taxes on dividends @ 15% in one stroke on behalf of the investors.
The biggest flaw in the above-mentioned system was that it provided equity but not equality in an economy which has the progressive nature of taxes being deep-rooted in its tax culture. The indirect effect was for a small investor paying taxes @ 15% on his small dividend amount. On the other hand, to bring equality, the government in Budget 2016 announced a super-rich tax @ 10% for receipt of dividends exceedings INR 1 Million which ultimately lead to multiple layers of taxation.
With the technological advancement in tracking the dividends payouts, it is now easy to link dividends directly to the income of the taxpayer. Considering the same, Budget 2020 has proposed dividends to be taxed in the hands of the shareholder. It is important therefore to understand what would change post 1 April 2020 for an investor like you and also for the companies that are investors including the foreign investor companies.
Top 4 impacts for individual investors:
Top 6 impacts for foreign and domestic investor companies
With the wave of complexity around the topic, it is recommended for an investor to seek a well rounded professional advice on the taxability of dividend and prepare himself towards additional compliance requirements for dividend income.
Includes some thoughts by Mr. Ramesh Khaitan – Sr. Vice President (Direct Taxes) – Lupin Pharma group.
Written and conceptualised by CA. Akshay Kenkre
Any comments please write to us at info@transprice.in
Comments are closed